Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report
Delayed Quote. Delayed Xetra - 11/27 11:35:25 am
38.07 EUR   +1.06%
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
RE
11/26FRESENIUS SE : DZ Bank keeps its Buy rating
MD
11/24FRESENIUS SE : UBS remains Neutral
MD
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : 3Q Net Profit Fell Less Than Expected; Backs 2020 Outlook

10/29/2020 | 01:32am EST

By Mauro Orru

Fresenius SE & Co. said Thursday that net income before special items for the third quarter fell, while sales rose slightly, and backed its 2020 outlook.

The German health-care company said net income before special items fell 4% to 427 million euros ($501.6 million), beating a Vara Research consensus of EUR418 million.

Earnings before interest and taxes before special items for the quarter fell 3% to EUR1.11 billion, 1% ahead of consensus.

Sales rose 1% to EUR8.92 billion compared with consensus of EUR8.88 billion.

Fresenius said the coronavirus pandemic would continue to harm operations in the fourth quarter, but backed its guidance for 2020 sales growth between 3% to 6% at constant currencies and for net income to fall up to 4% or rise up to 1% at constant currencies.

At Fresenius Medical Care AG & Co, the company's dialysis division, third-quarter net profit rose to EUR354 million from EUR333 million, while revenue remained largely flat at EUR4.41 billion.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

10-29-20 0231ET

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.83% 70.82 Delayed Quote.7.37%
FRESENIUS SE & CO. KGAA 1.06% 38.07 Delayed Quote.-24.13%
All news about FRESENIUS SE & CO. KGAA
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
RE
11/26FRESENIUS SE : DZ Bank keeps its Buy rating
MD
11/24FRESENIUS SE : UBS remains Neutral
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : RBC reiterates its Neutral rating
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
MD
11/19FRESENIUS SE : Bernstein reiterates its Buy rating
MD
11/19FRESENIUS SE & CO. KGAA : Preliminary announcement of the publication of quarter..
EQ
11/19FRESENIUS SE & CO. KGAA : Preliminary announcement of the publication of financi..
EQ
11/17FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies reiterates its Neutral rating
MD
11/13FRESENIUS SE : Receives a Buy rating from Bernstein
MD
More news
Financials
Sales 2020 36 301 M 43 427 M 43 427 M
Net income 2020 1 790 M 2 141 M 2 141 M
Net Debt 2020 24 198 M 28 948 M 28 948 M
P/E ratio 2020 12,0x
Yield 2020 2,10%
Capitalization 21 223 M 25 374 M 25 389 M
EV / Sales 2020 1,25x
EV / Sales 2021 1,12x
Nbr of Employees 309 114
Free-Float 72,0%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 49,67 €
Last Close Price 38,07 €
Spread / Highest target 78,6%
Spread / Average Target 30,5%
Spread / Lowest Target -53,6%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors